In:
Journal of the Korean Neurological Association, Korean Neurological Association, Vol. 40, No. 2 ( 2022-05-01), p. 176-180
Abstract:
Monoclonal antibodies are pure antibodies that react to a specific epitope. Plasmapheresis is a treatment that separates and eliminates disease-causing substances before replacing the blood with plasma. Plasmapheresis has insufficient evidence for treating new-onset refractory status epilepticus (NORSE). Sequential plasmaphereses gradually improved a female cryptogenic NORSE patient who did not benefit from monoclonal antibody treatment.
Type of Medium:
Online Resource
ISSN:
1225-7044
,
2288-985X
DOI:
10.17340/jkna.2022.2.14
Language:
English
Publisher:
Korean Neurological Association
Publication Date:
2022
Permalink